Literature DB >> 10697117

Continuous erythropoietin delivery by muscle-targeted gene transfer using in vivo electroporation.

H Maruyama1, M Sugawa, Y Moriguchi, I Imazeki, Y Ishikawa, K Ataka, S Hasegawa, Y Ito, N Higuchi, J J Kazama, F Gejyo, J I Miyazaki.   

Abstract

It has been demonstrated that gene transfer by in vivo electroporation of mouse muscle increases the level of gene expression by more than 100-fold over simple plasmid DNA injection. We tested continuous rat erythropoietin (Epo) delivery by this method in normal rats, using plasmid DNA expressing rat Epo (pCAGGS-Epo) as the vector. A pair of electrodes was inserted into the thigh muscles of rat hind limbs and 100 microg of pCAGGS-Epo was injected between the electrodes. Eight 100-V, 50-msec electric pulses were delivered through the electrodes. Each rat was injected with a total of 400 microg of pCAGGS-Epo, which was delivered to the medial and lateral sides of each thigh. The presence of vector-derived Epo mRNA at the DNA injection site was confirmed by RT-PCR. The serum Epo levels peaked at 122.2 +/- 33.0 mU/ml on day 7 and gradually decreased to 35.9 +/- 18.2 mU/ml on day 32. The hematocrit levels increased continuously, from the preinjection level of 49.5 +/- 1.1 to 67.8 +/- 2.2% on day 32 (p < 0.001). In pCAGGS-Epo treated rats, endogenous Epo secretion was downregulated on day 32. In a control experiment, intramuscular injection of pCAGGS-Epo without subsequent electroporation did not significantly enhance the serum Epo levels. These results demonstrate that muscle-targeted pCAGGS-Epo transfer by in vivo electroporation is a useful procedure for the continuous delivery of Epo.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10697117     DOI: 10.1089/10430340050015897

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  7 in total

1.  The effects of anti-inflammatory and anti-angiogenic DNA vaccination on diabetic nephropathy in rats.

Authors:  Peter Celec; Július Hodosy; Roman Gardlík; Michal Behuliak; Roland Pálffy; Marek Pribula; Peter Jáni; Ján Turňa; Katarína Sebeková
Journal:  Hum Gene Ther       Date:  2012-01-26       Impact factor: 5.695

2.  Naked plasmid DNA-based alpha-galactosidase A gene transfer partially reduces systemic accumulation of globotriaosylceramide in Fabry mice.

Authors:  Gen Nakamura; Hiroki Maruyama; Satoshi Ishii; Masaaki Shimotori; Shigemi Kameda; Toru Kono; Jun-ichi Miyazaki; Ashok B Kulkarni; Fumitake Gejyo
Journal:  Mol Biotechnol       Date:  2007-10-13       Impact factor: 2.695

3.  Rat liver-targeted naked plasmid DNA transfer by tail vein injection.

Authors:  Hiroki Maruyama; Noboru Higuchi; Shigemi Kameda; Jun-Ichi Miyazaki; Fumitake Gejyo
Journal:  Mol Biotechnol       Date:  2004-02       Impact factor: 2.695

4.  Rat kidney-targeted naked plasmid DNA transfer by retrograde injection into the renal vein.

Authors:  Hiroki Maruyama; Noboru Higuchi; Shigemi Kameda; Gen Nakamura; Seitaro Iguchi; Jun-Ichi Miyazaki; Fumitake Gejyo
Journal:  Mol Biotechnol       Date:  2004-05       Impact factor: 2.695

5.  Long-term and stable correction of uremic anemia by intramuscular injection of plasmids containing hypoxia-regulated system of erythropoietin expression.

Authors:  Jifeng Sun; Yarong Wang; Jie Yang; Dewei Du; Zhanting Li; Junxia Wei; Angang Yang
Journal:  Exp Mol Med       Date:  2012-11-30       Impact factor: 8.718

6.  Simultaneous gene transfer of bone morphogenetic protein (BMP) -2 and BMP-7 by in vivo electroporation induces rapid bone formation and BMP-4 expression.

Authors:  Mariko Kawai; Kazuhisa Bessho; Hiroki Maruyama; Jun-ichi Miyazaki; Toshio Yamamoto
Journal:  BMC Musculoskelet Disord       Date:  2006-08-03       Impact factor: 2.362

7.  Erythropoietin over-expression protects against diet-induced obesity in mice through increased fat oxidation in muscles.

Authors:  Pernille Hojman; Camilla Brolin; Hanne Gissel; Claus Brandt; Bo Zerahn; Bente Klarlund Pedersen; Julie Gehl
Journal:  PLoS One       Date:  2009-06-12       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.